China’s NMPA approves Sintbilo for primary hypercholesterolemia and dyslipidemia – Innovent Biologics
Innovent Biologics announces that China’s National Medical Products Administration (NMPA) has approved Sintbilo (tafolecimab injection, anti-PCSK9 monoclonal antibody) for the treatment of adult patients with primary hypercholesterolemia (including… read more.
